Research is the answer to one day making FA a treatable, manageable disease. Here, you'll discover the most recent strides in FA research and activities funded by FCF. Every quarter, we'll bring you updates on newly funded grants, ongoing projects, and significant milestones.
The David B. Frohnmayer Early Investigator Award was inaugurated in 2015, months after FARF co-founder Dave Frohnmayer passed away. One of his most salient leadership traits was his ability to recognize talent in others and inspire them to solve important...
Announcements
Mutations in 23 Fanconi anemia (FA) genes cause defects in DNA repair, which leads to chromosome instability, bone marrow failure, malformations, and susceptibility to cancer. The most well-described role of FA genes in DNA repair is known as the “canonical”...
Announcements
One of FARF’s guiding principles is to gather researchers and clinicians in the FA community every year to share updates in research and care. In September 2019, we held the 31st Fanconi Anemia Scientific Symposium in Chicago, Ill. Forty-four presenters...
Stories
My wife, Jolandie, and I had a pretty good thing going back in our hometown of Mbombela, South Africa. By age 25, I had successfully owned and operated two reputable businesses, had a lovely home, and plenty of people we...
Stories
What motivates me to work on FA: The patients and the families; that is clear for me. When I was an undergraduate student, I realized that I would like to work in genetic engineering to correct inherited disorders, but I...
Announcements
New approaches are needed for both prevention and treatment of squamous cell carcinoma (SCC) in patients with FA - approaches that have fewer and less severe side effects than chemotherapy and radiation therapy. The purpose of this Phase 2 study...
Announcements
